 |
 Video: What is a Stock Split?
|
|
|
| Conduit Pharmaceuticals, Inc. is a disease agnostic life science company. Co. is engaged in the development and commercialization of clinical assets to address the unmet medical needs of patients. Co.'s licensed clinical assets are focused on idiopathic male infertility and autoimmune diseases or immunodeficient conditions like uveitis, preterm labor, renal transplant rejection and Hashimoto's Thyroiditis. Co.'s asset pipeline includes AZD1656 (a Glucokinase Activator), and AZD5904 (a Myeloperoxidase Inhibitor). AZD1656 is a glucokinase activator used in diabetes mellitus. According to our CDT split history records, Conduit Pharmaceuticals has had 3 splits. | |
|
Conduit Pharmaceuticals (CDT) has 3 splits in our CDT split history database. The first split for CDT took place on January 02, 1996. This was a 3 for 2
split, meaning for each 2
shares of CDT owned pre-split, the shareholder now owned 3 shares. For example, a 1000 share position pre-split, became a 1500 share position following the split. CDT's second split took place on January 12, 1998. This was a 3 for 2
split, meaning for each 2
shares of CDT owned pre-split, the shareholder now owned 3 shares. For example, a 1500 share position pre-split, became a 2250 share position following the split. CDT's third split took place on August 22, 2000. This was a 3 for 2 split, meaning for each 2 shares of CDT owned pre-split, the shareholder now owned 3 shares. For example, a 2250 share position pre-split, became a 3375 share position following the split.
When a company such as Conduit Pharmaceuticals splits its shares, the market capitalization before and after the split takes place remains stable, meaning the shareholder now owns more shares but each are valued at a lower price per share. Often, however, a lower priced stock on a per-share basis can attract a wider range of buyers. If that increased demand causes the share price to appreciate, then the total market capitalization rises post-split. This does not always happen, however, often depending on the underlying fundamentals of the business.
Looking at the CDT split history from start to finish, an original position size of 1000 shares would have turned into 3375 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Conduit Pharmaceuticals shares, starting with a $10,000 purchase of CDT, presented on a split-history-adjusted basis factoring in the complete CDT split history.
Growth of $10,000.00
Without Dividends Reinvested
|
| Start date: |
03/29/2022 |
|
| End date: |
12/09/2024 |
|
| Start price/share: |
$10.10 |
|
| End price/share: |
$0.09 |
|
| Dividends collected/share: |
$0.00 |
|
| Total return: |
-99.11% |
|
| Average Annual Total Return: |
-82.58% |
|
| Starting investment: |
$10,000.00 |
|
| Ending investment: |
$89.08 |
|
| Years: |
2.70 |
|
|
|
| Date |
Ratio |
| 01/02/1996 | 3 for 2
| | 01/12/1998 | 3 for 2
| | 08/22/2000 | 3 for 2 |
|
|
